
DRAWINGS

Fig. 1






Fig. 2



GI50 ratio
0
2
4
6
8
10
12
14
16
Compound A
Comparative Compound
Gefitinib
Erlotinib
Afatinib

Fig. 3



Solvent Control
Afatinib 20 mg/kg
Compound A 200 mg/kg
RTV
35
30
25
20
15
10
5
0
0
7
14
Day
*

Fig. 4



Solvent Control
Afatinib 20 mg/kg
Compound A 200 mg/kg
Body Weight Change (%)
30
20
10
0
-10
-20
-30
0
7
14
Day

Fig. 5



Solvent Control
Afatinib 20 mg/kg
Compound A 200 mg/kg
RTV
0
2
4
6
8
10
12
0
7
14
Day
*

Fig. 6



Solvent Control
Afatinib 20 mg/kg
Compound A 200 mg/kg
Body Weight Change (%)
20
15
10
5
0
-5
-10
-15
-20
0
7
14
Day

Fig. 7



Solvent Control
Afatinib 20 mg/kg
Compound A 200 mg/kg
RTV
12
10
8
6
4
2
0
0
7
14
Day
*

Fig. 8



Solvent Control
Afatinib 20 mg/kg
Compound A 200 mg/kg
Body Weight Change (%)
20
15
10
5
0
-5
-10
-15
-20
0
7
14
Day

Fig. 9



Solvent Control
Compound A 100 mg/kg
Compound A 200 mg/kg
Afatinib 20 mg/kg
Tumor Volume (mm³)
5000
4000
3000
2000
1000
0
0
2
4
6
8
10
12
Day
*
*
*

Fig. 10



Solvent Control
Compound A 100 mg/kg
Compound A 200 mg/kg
Afatinib 20 mg/kg
Body Weight Change (%)
20
10
0
-10
-20
0
2
4
6
8
10
12
Day

Fig. 11



Solvent Control
Compound A 20 mg/kg
Compound A 40 mg/kg
Tumor Volume (mm3)
4000
3000
2000
1000
0
0
2
4
6
8
10
12
14
16
Day
**

Fig. 12



Solvent Control
Compound A 20 mg/kg
Compound A 40 mg/kg
Body Weight Change (%)
20
10
0
−10
−20
0
2
4
6
8
10
12
14
16
Day

Fig. 13



Solvent Control
Afatinib 20 mg/kg
Compound A 100 mg/kg
Compound A 200 mg/kg
Tumor Volume (mm3)
Day
Dosing Period
Observation Period
*
*

Fig. 14



Solvent Control
Afatinib 20 mg/kg
Compound A 100 mg/kg
Compound A 200 mg/kg
Body Weight Change (%)
20
15
10
5
0
-5
-10
-15
-20
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42
Day
Dosing Period
Observation Period

Fig. 15

Wild-type EGFR (Accession number NP_005219.2)

```
   1 mrpsgtagaa llallaalcp asraleekkv cqgtsnkltq lgtfedhfls lqrmfnncev
  61 vlgnleityv qrnydlsflk tiqevagyvl ialntverip lenlqiirgn myyensyala
 121 vlsnydankt glkelpmrnl qeilhgavrf snnpalcnve siqwrdivss dflsnmsmdf
 181 qnhlgscqkc dpscpngscw gageencqkl tkiicaqqcs grcrgkspsd cchnqcaagc
 241 tgpresdclv crkfrdeatc kdtcpplmly nptyqmdvn pegkysfgat cvkkcprnyv
 301 vtdhgscvra cgadsyemee dgvrkckkce gpcrkvcngi gigefkdsls inatnikhfk
 361 nctsisgdlh ilpvafrgds fthtppldpq eldilktvke itgflliqaw penrtdlhaf
 421 enleiirgrt kqhgqfslav vslnitslgl rslkeisdgd viisgnknlc yantinwkkl
 481 fgtsgqktki isnrgensck atgqvchalc spegcwgpep rdcvscrnvs rgrecvdkcn
 541 llegeprefv enseciqchp eclpqamnit ctgrgpdnci qcahyidgph cvktcpagvm
 601 genntlvwky adaghvchlc hpnctygctg pglegcptng pkipsiatgm vgallllvv
 661 algiglfmrr rhivrkrtlr rllqerelve pltpsgeapn qallrilket efkkikvlgs
 721 gafgtvykgl wipegekvki pvaikelrea tspkankeil deayvmasvd nphvcrllgi
 781 cltstvqlit qlmpfgclld yvrehkdnig sqyllnwcvq iakgmnyled rrlvhrdlaa
 841 rnvlvktpqh vkitdfglak llgaeekeyh aeggkvpikw malesilhri ythqsdvwsy
 901 gvtvwelmtf gskpydgipa seissilekg erlpqppict idvymimvkc wmidadsrpk
 961 freliiefsk mardpqrylv iqgdermhlp sptdsnfyra lmdeedmddv vdadeylipq
1021 qgffsspsts rtpllsslsa tsnnstvaci drnglqscpi kedsflqrys sdptgalted
1081 siddtflpvp eyinqsvpkr pagsvqnpvy hnqplnpaps rdphyqdphs tavgnpeyln
1141 tvqptcvnst fdspahwaqk gshqisldnp dyqqdffpke akpngifkgs taenaeylrv
1201 apqssefiga
```